Daily Medication Pearl: Bevespi (Glycopyrrolate/Formoterol)
Bevespi is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.
Medication Pearl of the Day: Bevespi (Glycopyrrolate/Formoterol)
Indication: Bevespi is a combination of glycopyrrolate, an anticholinergic, and formoterol fumarate, a long-acting beta2-adrenergic agonist (beta2-agonist) indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.
- Dosing: Patients should take 2 inhalations of Bevespi twice daily.
- Dosage forms: As an inhalation aerosol, Bevespi is a pressurized metered dose inhaler containing a combination of glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg).
- Adverse events (AEs): The most common AEs (incidence ≥2% and more common than with placebo) include urinary tract infection and cough.
- Mechanism of action: Glycopyrrolate is a long-acting antimuscarinic agent which is often referred to as an anticholinergic. Formoterol fumarate is a long-acting selective beta2-agonist with a rapid onset of action.
- Manufacturer: AstraZeneca
US FDA. Label Prescribing Information. US FDA website. Revised April 2016. Accessed Dec 20, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208294s000lbl.pdf